Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial

Breast Cancer Research and Treatment

Volumn 128, Issue 3, 2011, Pages 783-794

  Hadad, Sirwan ^a   Iwamoto, Takayuki ^b   Jordan, Lee ^a   Purdie, Colin ^a   Bray, Susan ^a   Baker, Lee ^a   Jellema, Gera ^c   Deharo, Steve ^c   Hardie, D Grahame ^d   Pusztai, Lajos ^b   Moulder Thompson, Stacy ^b   Dewar, John A ^a   Thompson, Alastair M ^a,b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Almac Sciences   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Breast cancer; Clinical trial; ki67; Metformin; Transcriptome analyses

Indexed keywords

BRCA1 PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN CDC42; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGED; ARTICLE; BLOATING; BREAST BIOPSY; BREAST CANCER; BREAST SURGERY; CCDC14 GENE; CELL COUNT; CELL CYCLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DOWN REGULATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; NAUSEA; PDE3B GENE; PILOT STUDY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SSR3 GENE; TP53 GENE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KI-67 ANTIGEN; METFORMIN; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79960845901     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1612-1     Document Type: Article

References (30)

1. JM Evans LA Donnelly AM Emslie-Smith DR Alessi AD Morris 2005 Metformin and reduced risk of cancer in diabetic patients BMJ 330 7503 1304 1305 15849206 10.1136/bmj.38415.708634.F7 (Pubitemid 40813563)
2. M Monami C Lamanna D Balzi N Marchionni E Mannucci 2009 Sulphonylureas and cancer: a case-control study Acta Diabetol 46 4 279 284 19082520 10.1007/s00592-008-0083-2 1:CAS:528:DC%2BD1MXhtlKjt7rM
3. S Jiralerspong SL Palla SH Giordano F Meric-Bernstam C Liedtke CM Barnett, et al. 2009 Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer J Clin Oncol 27 20 3297 3302 19487376 10.1200/JCO.2009.19.6410 1:CAS:528:DC%2BD1MXpvFejt74%3D
4. G Zhou R Myers Y Li Y Chen X Shen J Fenyk-Melody, et al. 2001 Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest 108 8 1167 1174 11602624 1:CAS:528:DC%2BD3MXns1ChsL4%3D (Pubitemid 32995375)
5. SA Hawley FA Ross C Chevtzoff KA Green A Evans S Fogarty, et al. 2010 Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation Cell Metab 11 6 554 565 20519126 10.1016/j.cmet.2010.04.001 1:CAS:528:DC%2BC3cXnsFyit7w%3D
6. DG Hardie 2007 AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy Nat Rev Mol Cell Biol 8 10 774 785 17712357 10.1038/nrm2249 1:CAS:528:DC%2BD2sXhtVKmt7vP (Pubitemid 47462132)
7. BB Kahn T Alquier D Carling DG Hardie 2005 AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism Cell Metab 1 1 15 25 16054041 10.1016/j.cmet.2004.12.003 1:CAS:528: DC%2BD2MXhtlaqs74%3D (Pubitemid 43960587)
8. IP Salt G Johnson SJ Ashcroft DG Hardie 1998 AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release Biochem J 335 Pt 3 533 539 9794792 1:CAS:528:DyaK1cXnsFeku78%3D (Pubitemid 28515405)
9. AS Marsin L Bertrand MH Rider J Deprez C Beauloye MF Vincent, et al. 2000 Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia Curr Biol 10 20 1247 1255 11069105 10.1016/S0960-9822(00)00742-9 1:CAS:528:DC%2BD3cXotVSrsrw%3D
10. M Zakikhani R Dowling IG Fantus N Sonenberg M Pollak 2006 Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells Cancer Res 66 21 10269 10273 17062558 10.1158/0008-5472.CAN-06-1500 1:CAS:528:DC%2BD28XhtFGjsrvK (Pubitemid 44799743)
11. SM Hadad S Fleming AM Thompson 2008 Targeting AMPK: a new therapeutic opportunity in breast cancer Crit Rev Oncol Hematol 67 1 1 7 18343152 10.1016/j.critrevonc.2008.01.007
12. Y Zhuang WK Miskimins 2008 Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1 J Mol Signal 3 18 19046439 10.1186/1750-2187-3-18
13. B van der Burg GR Rutteman MA Blankenstein SW de Laat EJ van Zoelen 1988 Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and estrogen J Cell Physiol 134 1 101 108 3275677 10.1002/jcp.1041340112 (Pubitemid 18034935)
14. SM Hadad L Baker PR Quinlan KE Robertson SE Bray G Thomson, et al. 2009 Histological evaluation of AMPK signalling in primary breast cancer BMC Cancer 9 1 307 19723334 10.1186/1471-2407-9-307
15. PJ Goodwin V Stambolic J Lemieux BE Chen WR Parulekar KA Gelmon, et al. 2011 Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents Breast Cancer Res Treat 126 1 215 220 20976543 10.1007/s10549-010-1224-1 1:CAS:528: DC%2BC3MXpvFWhsg%3D%3D
16. B Vojtesek J Bartek CA Midgley DP Lane 1992 An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53 J Immunol Methods 151 1-2 237 244 1378473 10.1016/0022-1759(92)90122-A 1:CAS:528:DyaK38XlsVKlsr8%3D
17. S Detre G Saclani Jotti M Dowsett 1995 A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas J Clin Pathol 48 9 876 878 7490328 10.1136/jcp.48.9.876 1:STN:280:DyaK28%2Fps1arsQ%3D%3D
18. JM Harvey GM Clark CK Osborne DC Allred 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 5 1474 1481 10334533 1:STN:280:DyaK1M3msFOjsA%3D%3D (Pubitemid 29220854)
19. CA Purdie LB Jordan JB McCullough SL Edwards J Cunningham M Walsh, et al. 2010 HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma Histopathology 56 6 702 707 20546335 10.1111/j.1365-2559.2010.03533.x
20. R Yerushalmi R Woods PM Ravdin MM Hayes KA Gelmon 2010 Ki67 in breast cancer: prognostic and predictive potential Lancet Oncol 11 2 174 183 20152769 10.1016/S1470-2045(09)70262-1 1:CAS:528:DC%2BC3cXhtlGgtbc%3D
21. E de Azambuja F Cardoso G de Castro M Colozza Jr MS Mano V Durbecq, et al. 2007 Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 10 1504 1513 17453008 10.1038/sj.bjc.6603756 (Pubitemid 46762956)
22. MC Cheang SK Chia D Voduc D Gao S Leung J Snider, et al. 2009 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 10 736 750 19436038 10.1093/jnci/djp082 1:CAS:528: DC%2BD1MXmtlyit74%3D
23. JA Vendrell KE Robertson P Ravel SE Bray A Bajard CA Purdie, et al. 2008 A candidate molecular signature associated with tamoxifen failure in primary breast cancer Breast Cancer Res 10 5 R88 18928543 10.1186/bcr2158
24. YH Choi S Park S Hockman E Zmuda-Trzebiatowska F Svennelid M Haluzik, et al. 2006 Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice J Clin Invest 116 12 3240 3251 17143332 10.1172/JCI24867 1:CAS:528:DC%2BD28XhtlWgsbnP (Pubitemid 44878638)
25. L Harndahl N Wierup S Enerback H Mulder VC Manganiello F Sundler, et al. 2004 Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology J Biol Chem 279 15 15214 15222 14736883 10.1074/jbc.M308952200 (Pubitemid 38618917)
26. E Zmuda-Trzebiatowska A Oknianska V Manganiello E Degerman 2006 Role of PDE3B in insulin-induced glucose uptake, GLUT-4 translocation and lipogenesis in primary rat adipocytes Cell Signal 18 3 382 390 15961276 10.1016/j.cellsig. 2005.05.007 1:CAS:528:DC%2BD2MXht1GhsLzL (Pubitemid 41661353)
27. B Vogelstein D Lane AJ Levine 2000 Surfing the p53 network Nature 408 6810 307 310 11099028 10.1038/35042675 1:CAS:528:DC%2BD3cXosVemtrY%3D
28. M Buzzai RG Jones RK Amaravadi JJ Lum RJ DeBerardinis F Zhao, et al. 2007 Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth Cancer Res 67 14 6745 6752 17638885 10.1158/0008-5472.CAN-06-4447 1:CAS:528:DC%2BD2sXnslOju7s%3D (Pubitemid 47105521)
29. LA Henry DA Johnson D Sarrio S Lee PR Quinlan T Crook, et al. 2011 Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome Oncogene 30 9 1046 1058 21042283 10.1038/onc.2010.488 1:CAS:528:DC%2BC3cXhtlKit73K
30. CD Lucke A Philpott JC Metcalfe AM Thompson L Hughes-Davies PR Kemp, et al. 2001 Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer Cancer Res 61 2 482 485 11212236 1:CAS:528:DC%2BD3MXht1Gmsrc%3D (Pubitemid 32128602)